Literature DB >> 30329163

5-aminolaevulinic acid nanoemulsion is more effective than methyl-5-aminolaevulinate in daylight photodynamic therapy for actinic keratosis: a nonsponsored randomized double-blind multicentre trial.

J E Räsänen1,2, N Neittaanmäki3, L Ylitalo2, J Hagman4,5, P Rissanen6, L Ylianttila7, M Salmivuori1, E Snellman2, M Grönroos1.   

Abstract

BACKGROUND: Daylight photodynamic therapy (DL-PDT) with methyl-5-aminolaevulinate (MAL) is an effective treatment for mild and moderate actinic keratosis (AK).
OBJECTIVES: To assess the clinical efficacy, tolerability and cost-effectiveness of 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) compared with MAL in DL-PDT for grade I-II AKs.
METHODS: This nonsponsored, prospective randomized double-blind multicentre trial included 69 patients with 767 grade I-II AKs located symmetrically on the face or scalp. A single DL-PDT was given in a randomized split-face design. The primary outcome was clearance of the AKs at 12 months as assessed by a blinded observer. The secondary outcomes were pain, treatment reactions, cosmetic outcome and the cost-effectiveness of the therapy.
RESULTS: In the per-patient (half-face) analysis, clearance was better for the BF-200 ALA sides than for those treated with MAL (P = 0·008). In total, BF-200 ALA cleared 299/375 AKs (79·7%) and MAL 288/392 (73·5%) (P = 0·041). The treatment was practically painless with both photosensitizers, the mean pain visual analogue scale being 1·51 for BF-200 ALA and 1·35 for MAL (P = 0·061). Twenty-six patients had a stronger skin reaction on the BF-200 ALA side, seven on the MAL side and 23 displayed no difference (P = 0·001). The cosmetic outcome was excellent or good in > 90% of cases with both photosensitizers (P = 1·000). The cost-effectiveness plane showed that the costs of DL-PDT were similar for both photosensitizers, but the effectiveness was slightly higher for BF-200 ALA.
CONCLUSIONS: Our results indicate that BF-200 ALA is more effective than MAL in DL-PDT for grade I-II AKs. BF-200 ALA provides slightly better value for money than MAL.
© 2018 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30329163     DOI: 10.1111/bjd.17311

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

Review 1.  Photodynamic Therapy with 5-aminolevulinic Acid 10% Gel and Red Light for the Treatment of Actinic Keratosis, Nonmelanoma Skin Cancers, and Acne: Current Evidence and Best Practices.

Authors:  Nathalie C Zeitouni; Neal Bhatia; Roger I Ceilley; Joel L Cohen; James Q Del Rosso; Angela Y Moore; Gilly Munavalli; David M Pariser; Todd Schlesinger; Daniel M Siegel; Andrea Willey; Mitchel P Goldman
Journal:  J Clin Aesthet Dermatol       Date:  2021-10

2.  Topical Photodynamic Therapy with Different Forms of 5-Aminolevulinic Acid in the Treatment of Actinic Keratosis.

Authors:  Joanna Bartosińska; Paulina Szczepanik-Kułak; Dorota Raczkiewicz; Marta Niewiedzioł; Agnieszka Gerkowicz; Dorota Kowalczuk; Mirosław Kwaśny; Dorota Krasowska
Journal:  Pharmaceutics       Date:  2022-02-01       Impact factor: 6.321

Review 3.  The Role and Effectiveness of Photodynamic Therapy on Patients With Actinic Keratosis: A Systematic Review and Meta-Analysis.

Authors:  George Mpourazanis; Wolfgang Konschake; Romanos Vogiatzis; Petros Papalexis; Vasiliki E Georgakopoulou; Georgios Ntritsos; Pagona Sklapani; Nikolaos Trakas
Journal:  Cureus       Date:  2022-06-28

Review 4.  Measuring Daylight: A Review of Dosimetry in Daylight Photodynamic Therapy.

Authors:  Paul O'Mahoney; Marina Khazova; Ewan Eadie; Sally Ibbotson
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.